Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

BCL6 PROTAC degrader ARVN-71228 shows efficacy in preclinical models of DLBCL

Dec. 15, 2021

Panbela's SBP-101 shows preclinical promise for ovarian cancer

Dec. 15, 2021

CVL-218 shows promising potency and safety in preclinical models

Dec. 14, 2021

Targeting CXCL16 shows therapeutic effects in model of TNBC

Dec. 14, 2021

Fochon Pharmaceuticals patents PI3K inhibitors

Dec. 14, 2021

Beijing Tide Pharmaceutical discloses new ATR kinase inhibitors

Dec. 14, 2021

WNK2 is differentially expressed in MYD88-mutated Waldenstrom macroglobulinemia

Dec. 14, 2021

Clonal fitness study may steer future cancer therapy

Dec. 14, 2021

Lilly and Foghorn collaborate on Foghorn's selective BRM program and additional programs

Dec. 13, 2021

Tonix and Columbia University to explore rTFF2-based therapy for gastric and colorectal cancers

Dec. 13, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Novartis to pay $1.5B for Myricx Bio and its novel ADC payloads
BioWorld
Novartis AG is to pay $1.1 billion up front to acquire Myricx Bio Ltd., a preclinical-stage antibody-drug conjugate (ADC) specialist that is advancing a novel and...